S
Steven M. Snapinn
Researcher at Amgen
Publications - 112
Citations - 15813
Steven M. Snapinn is an academic researcher from Amgen. The author has contributed to research in topics: Losartan & Left ventricular hypertrophy. The author has an hindex of 40, co-authored 109 publications receiving 15064 citations. Previous affiliations of Steven M. Snapinn include United States Military Academy & University of Copenhagen.
Papers
More filters
Journal ArticleDOI
Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy
Barry M. Brenner,Mark E. Cooper,Dick de Zeeuw,William F. Keane,William E. Mitch,Hans-Henrik Parving,Giuseppe Remuzzi,Steven M. Snapinn,Zhonxin Zhang,Shahnaz Shahinfar +9 more
TL;DR: Losartan conferred significant renal benefits in patients with type 2 diabetes and nephropathy, and it was generally well tolerated.
Journal ArticleDOI
Cardiovascular morbidity and mortality in patients with diabetes in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol.
Lars H Lindholm,Hans Ibsen,Björn Dahlöf,Richard B. Devereux,Gareth Beevers,Ulf de Faire,Frej Fyhrquist,Stevo Julius,Sverre E. Kjeldsen,Krister Kristiansson,Ole Lederballe-Pedersen,Markku S. Nieminen,Per Omvik,Suzanne Oparil,Hans Wedel,Peter Aurup,Jonathan M. Edelman,Steven M. Snapinn +17 more
TL;DR: Losartan was more effective than atenolol in reducing cardiovascular morbidity and mortality as well as mortality from all causes in patients with hypertension, diabetes, and LVH.
Journal ArticleDOI
Regression of electrocardiographic left ventricular hypertrophy during antihypertensive treatment and the prediction of major cardiovascular events.
Peter M. Okin,Richard B. Devereux,Sverker Jern,Sverre E. Kjeldsen,Stevo Julius,Markku S. Nieminen,Steven M. Snapinn,Katherine E. Harris,Peter Aurup,Jonathan M. Edelman,Hans Wedel,Lars H Lindholm,Björn Dahlöf +12 more
TL;DR: Less-severe electrocardiographic LVH by Cornell product and SokolowLyon voltage criteria during antihypertensive therapy is associated with lower likelihoods of CV morbidity and mortality, independent of blood pressure lowering and treatment modality in persons with essential hypertension.
Journal ArticleDOI
Albuminuria and Cardiovascular Risk in Hypertensive Patients with Left Ventricular Hypertrophy: The LIFE Study
Kristian Wachtell,Hans Ibsen,Michael H. Olsen,Knut Borch-Johnsen,Lars H Lindholm,Carl Erik Mogensen,Björn Dahlöf,Richard B. Devereux,Gareth Beevers,Ulf de Faire,Frej Fyhrquist,Stevo Julius,Sverre E. Kjeldsen,Krister Kristianson,Ole Lederballe-Pedersen,Markku S. Nieminen,Peter M. Okin,Per Omvik,Suzanne Oparil,Hans Wedel,Steven M. Snapinn,Peter Aurup +21 more
TL;DR: This large prospective study of hypertensive patients with left ventricular hypertrophy found that increasing albuminuria is associated with a graded increase in risk, and any threshold identified would be much lower than the threshold traditionally defined in diabetic populations.
Journal ArticleDOI
The risk of developing end-stage renal disease in patients with type 2 diabetes and nephropathy: the RENAAL study.
William F. Keane,Barry M. Brenner,Dick de Zeeuw,Jean-Pierre Grünfeld,Janet B. McGill,William E. Mitch,Artur B. Ribeiro,Shahnaz Shahinfar,Roger L. Simpson,Steven M. Snapinn,Robert D. Toto,Renaal Study Investigators +11 more
TL;DR: After control of blood pressure in type 2 diabetic patients with nephropathy, proteinuria, degree of renal failure, serum albumin, and hemoglobin level are independent risk factors that predict renal outcomes.